Home

About

I am a molecular biologist at the Medical University of Łódź, specializing in DNA damage and repair, oxidative stress, and immunometabolic pathways. My research emphasizes translating mechanistic insights into clinical applications, particularly in autoimmune diseases and cancer. With more than 100 publications in peer-reviewed international journals, my work is distinguished by robust interdisciplinary collaborations with clinical teams in gastroenterology, rheumatology, and medicinal chemistry.

I use a multidisciplinary approach integrating functional genomics, immunoprofiling, and computational biology to investigate how DNA damage response and other cellular stress pathways intersect with immune and metabolic networks. This systems-level perspective enables the identification of therapeutic targets and predictive biomarkers, connecting mechanistic understanding with translational medicine.

Main Research Areas

Gastrointestinal & Gut–Brain Axis Research (with Prof. Chojnacki)

I investigate the molecular basis of functional gastrointestinal disorders, focusing on immune-metabolic interactions and neuroendocrine pathways. My work integrates multi-omics approaches with clinical phenotyping to understand disease mechanisms in IBS, microscopic colitis, and SIBO. This research aims to identify precision biomarkers and therapeutic targets that advance personalized medicine in gastroenterology.

Medicinal Chemistry — Basic Biology of Novel Compounds (with Prof. Witczak)

My contribution focuses on characterizing the biological behavior of newly synthesized scaffolds in relevant cellular contexts—clarifying mechanisms of action, off-target liabilities, and structure–response relationships. I emphasize functional, pathway-level readouts rather than assay-specific details to understand how compounds alter stress responses, genome stability, and immune-related signaling. This work is designed to be pre-translational: it defines what the molecules do biologically before making any claims about therapeutic development.

Genome Stability & Cellular Stress Response

My research examines how cells maintain genomic integrity under various stress conditions, with particular emphasis on DNA damage response pathways. I study the relationship between repair capacity, treatment sensitivity, and disease progression across different pathological contexts. This work contributes to biomarker discovery and therapeutic strategy development in precision oncology.

  Autoimmunity & Translational Immunology

Using patient-derived samples, I investigate the molecular mechanisms underlying autoimmune diseases, focusing on the interplay between genomic instability, oxidative stress, and immune dysfunction. My research aims to identify clinically relevant biomarkers for disease monitoring and risk stratification, while uncovering targetable pathways for therapeutic intervention.

Population Genetics & Precision Medicine

I analyze genetic variation in key biological pathways to understand disease susceptibility, progression patterns, and treatment responses. By integrating genomic data with clinical and environmental factors, I develop predictive models that support evidence-based patient stratification and personalized therapeutic approaches.

Current Research Interests

My research focuses on the gut-brain axis and tryptophan metabolism in functional and inflammatory disorders, investigating how gut microbiome dysregulation and altered tryptophan pathways contribute to IBS, SIBO, chronic fatigue syndrome, and lymphocytic colitis. I examine the impact of bacterial and neuroactive metabolites on both somatic and psychiatric symptoms, while evaluating targeted dietary interventions as precision therapeutic strategies.

I also investigate genomic instability and DNA repair in autoimmune disease pathogenesis, particularly examining how impaired DNA damage repair mechanisms contribute to rheumatoid arthritis and multiple sclerosis development. My work analyzes genetic polymorphisms in key repair genes and their correlation with disease risk, utilizing machine learning models to predict severe disease phenotypes based on genetic markers.

Additionally, I collaborate on developing novel targeted cancer therapies, focusing on the design and mechanistic evaluation of promising anticancer compounds. My recent work examines thiodiazole and thiazoline derivatives, demonstrating distinct cytotoxic mechanisms ranging from oxidative stress induction to apoptosis activation. I also explore strategies to overcome chemotherapy resistance in ovarian cancer through DNA repair pathway inhibition.